Tokyo, 15 November, 2012 –Astellas Pharma Inc. (Tokyo: 4503, ”Astellas”) announced today that it received a notice from AstraZeneca not to exercise an exclusive option to acquire the Phase II clinical and pre-clinical assets, PSN821 and PSN842 respectively, for the treatment of type 2 diabetes.

AstraZeneca and Prosidion Limited, a fully-owned subsidiary of Astellas, and Astellas have entered into an option agreement in December 2011, under which Prosidion granted to AstraZeneca the exclusive option to acquire these assets.

Astellas does not plan to make further development of PSN821 and PSN842.

Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)